Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model.
Bals. R R; Weiner. D J DJ; Meegalla. R L RL; Wilson. J M JM
Key Findings
- CF airway fluid normally fails to kill common lung pathogens.
- Adding the LL‑37 gene via adenovirus raised peptide levels 3‑4× above normal.
- The increased LL‑37 restored bacterial killing to levels seen in healthy tissue.
Practical Outcomes
- For biohackers, the work suggests that raising LL‑37 levels—whether through peptide supplements, inhalation, or other delivery methods—could enhance lung immunity, especially in people with compromised innate defenses. While viral gene transfer isn’t a DIY option, the data support exploring safe ways to increase LL‑37 locally (e.g., nasal sprays or nebulized peptides) as a potential anti‑infection strategy.
Summary
The study shows that boosting the natural antimicrobial peptide LL‑37 in the lungs of cystic fibrosis (CF) models can bring back the ability to kill harmful bacteria like Pseudomonas and Staph. By using a virus to deliver the LL‑37 gene, the researchers raised peptide levels three‑ to four‑fold, which was enough to restore normal bacterial killing.
Abstract
Recent studies suggest that the gene defect in cystic fibrosis (CF) leads to a breach in innate immunity. We describe a novel genetic strategy for reversing the CF-specific defect of antimicrobial activity by transferring a gene encoding a secreted cathelicidin peptide antibiotic into the airway epithelium grown in a human bronchial xenograft model. The airway surface fluid (ASF) from CF xenografts failed to kill Pseudomonas aeruginosa or Staphylococcus aureus. Partial reconstitution of CF transmembrane conductance regulator expression after adenovirus-mediated gene transfer restored the antimicrobial activity of ASF from CF xenografts to normal levels. Exposure of CF xenografts to an adenovirus expressing the human cathelicidin LL-37/hCAP-18 increased levels of this peptide in the ASF three- to fourfold above the normal concentrations, which were equivalent in ASF from CF and normal xenografts before gene transfer. The increase of LL-37 was sufficient to restore bacterial killing to normal levels. The data presented describe an alternative genetic approach to the treatment of CF based on enhanced expression of an endogenous antimicrobial peptide and provide strong evidence that expression of antimicrobial peptides indeed protects against bacterial infection.
Study Information
pubmed
1999
10.1172/jci6570